MedTrace Logo

Tolerance Study of the Dietary Supplement Lipidrive (ECPH1-03)

NCT03052062 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2018-07-06

No results posted yet for this study

Summary

The objectives of this clinical study are to determine the tolerance of dietary supplement Lipidrive through the evaluation of several parameters :

* Various blood biological parameters
* Urinary parameters
* Hemodynamic indicators
* Cardiac function
* Anthropometric variables

Conditions

Interventions

DIETARY_SUPPLEMENT

Lipidrive

LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day

Sponsors & Collaborators

  • University Hospital, Clermont-Ferrand

    collaborator OTHER

  • Université Blaise Pascal, Clermont-Ferrand

    collaborator OTHER

  • Biofortis Mérieux NutriSciences

    collaborator OTHER

  • Valbiotis

    lead INDUSTRY

Principal Investigators

  • Gisèle Pickering, MD, PhD · Centre d'Investigation Clinique INSERM 501, Clermont-Ferrand, France

  • Sébastien Peltier, PhD · Valbiotis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-02
Primary Completion
2018-07-03
Completion
2018-07-03

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03052062 on ClinicalTrials.gov